Association Study Confirmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han Women

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2017 Apr 15

PMID 28408616

Citations 11

Authors

Yihui Xu

Mengyun Chen

Chenchen Liu

Xiaowei Zhang

Wei Li

Huaidong Cheng

Jun Zhu

Mingjun Zhang

Zhendong Chen

Bo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is a heterogeneous and polygenic disease that can be divided into different molecular subtypes based on histological and genomic features. To date, numerous susceptibility loci of breast cancer have been discovered by genome-wide association studies and may expand the genetic features. However, few loci have been further studied according to molecular subtypes.

Materials And Methods: We genotyped 23 recently discovered single nucleotide polymorphisms using the Sequenom iPLEX platform in a female Chinese cohort of 3,036 breast cancer patients (2,935 samples matched molecular subtypes) and 3,036 healthy controls.

Results: Through a stratification analysis, (rs16886034, rs16886364, rs16886397, rs1017226, rs16886448) and (rs4593472) were associated with Luminal A, and (rs35054928) was associated with Luminal B.

Conclusion: In our study, breast cancer-specific molecular subtype-associated susceptibility loci were confirmed in Chinese Han women, which contributes to a better genetic understanding of breast cancer in different molecular subtypes.

Implications For Practice: To date, genome-wide association studies have identified more than 90 susceptibility loci associated with breast cancer. However, few loci have been further studied according to molecular subtype. The results of this study are that breast cancer-specific molecular subtype-associated susceptibility loci were confirmed in Chinese Han women, which contributes to a better genetic understanding of breast cancer in different molecular subtypes.

Citing Articles

Assessment of genetic polymorphisms and esophageal squamous cell carcinoma risk in the Hainan Han population.

Tu R, Zhong D, Li P, Li Y, Chen Z, Hu F Ann Med. 2024; 56(1):2397569.

PMID: 39221756 PMC: 11370687. DOI: 10.1080/07853890.2024.2397569.

Molecular typing and prognostic risk models for ovarian cancer: a study based on cell differentiation trajectory.

Chen T, Ni T, Mu L, Ying Z, Zhang H, Wang Z Front Cell Dev Biol. 2023; 11:1131494.

PMID: 37719881 PMC: 10500593. DOI: 10.3389/fcell.2023.1131494.

Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.

Xiao M, He J, Yin L, Chen X, Zu X, Shen Y Front Immunol. 2022; 12:799428.

PMID: 34992609 PMC: 8724912. DOI: 10.3389/fimmu.2021.799428.

The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).

Al-Kawaz A, Ali R, Toss M, Miligy I, Mohammed O, Green A Breast Cancer Res Treat. 2021; 190(1):39-51.

PMID: 34406589 PMC: 8557137. DOI: 10.1007/s10549-021-06357-7.

rs12537 Is a Novel Susceptibility SNP Associated With Estrogen Receptor Positive Breast Cancer in Chinese Han Population.

Xu J, Li G, Chen M, Li W, Wu Y, Zhang X Front Med (Lausanne). 2021; 8:708644.

PMID: 34395483 PMC: 8355624. DOI: 10.3389/fmed.2021.708644.

References

Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y . Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2011; 105(8):773-9. DOI: 10.1002/jso.22120. View

Dieci M, Arnedos M, Andre F, Soria J . Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3(3):264-79. DOI: 10.1158/2159-8290.CD-12-0362. View

Zhang B, Li Y, Li L, Chen M, Zhang C, Zuo X . Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. Breast Cancer Res Treat. 2014; 146(3):503-14. DOI: 10.1007/s10549-014-3041-4. View

Xu W, Shu X, Long J, Lu W, Cai Q, Zheng Y . Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Am J Epidemiol. 2011; 173(8):923-31. PMC: 3071853. DOI: 10.1093/aje/kwq460. View

Gatza M, Lucas J, Barry W, Kim J, Wang Q, Crawford M . A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A. 2010; 107(15):6994-9. PMC: 2872436. DOI: 10.1073/pnas.0912708107. View

Stacey S, Manolescu A, Sulem P, Thorlacius S, Gudjonsson S, Jonsson G . Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008; 40(6):703-6. DOI: 10.1038/ng.131. View

Easton D, Pooley K, Dunning A, Pharoah P, Thompson D, Ballinger D . Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148):1087-93. PMC: 2714974. DOI: 10.1038/nature05887. View

Small G, Shi Y, Higgins L, Orlowski R . Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 2007; 67(9):4459-66. DOI: 10.1158/0008-5472.CAN-06-2644. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

10.

Couch F, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker K . Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 2013; 9(3):e1003212. PMC: 3609646. DOI: 10.1371/journal.pgen.1003212. View

11.

Ignatiadis M, Sotiriou C . Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013; 10(9):494-506. DOI: 10.1038/nrclinonc.2013.124. View

12.

Serrano-Gomez S, Sanabria-Salas M, Hernandez-Suarez G, Garcia O, Silva C, Romero A . High prevalence of luminal B breast cancer intrinsic subtype in Colombian women. Carcinogenesis. 2016; 37(7):669-676. PMC: 4936382. DOI: 10.1093/carcin/bgw043. View

13.

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E . Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014; 32(25):2794-803. DOI: 10.1200/JCO.2013.54.1870. View

14.

Liang H, Yang X, Chen L, Li H, Zhu A, Sun M . Heterogeneity of Breast Cancer Associations with Common Genetic Variants in FGFR2 according to the Intrinsic Subtypes in Southern Han Chinese Women. Biomed Res Int. 2015; 2015:626948. PMC: 4573424. DOI: 10.1155/2015/626948. View

15.

Cheng C, Hu W, Liu L, Li J . Fibroblast growth factor receptor 2: a new potential therapeutic target for human cancer. Hum Pathol. 2014; 46(2):339-40. DOI: 10.1016/j.humpath.2014.10.012. View

16.

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

17.

Small K, Hedman A, Grundberg E, Nica A, Thorleifsson G, Kong A . Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet. 2011; 43(6):561-4. PMC: 3192952. DOI: 10.1038/ng.833. View

18.

Popejoy A, Fullerton S . Genomics is failing on diversity. Nature. 2016; 538(7624):161-164. PMC: 5089703. DOI: 10.1038/538161a. View

19.

Watters J, Campbell J, Cunningham M, KREBS E, Dorsa D . Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology. 1997; 138(9):4030-3. DOI: 10.1210/endo.138.9.5489. View

20.

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View